Form 8-K - Current report:
SEC Accession No. 0001193125-24-159933
Filing Date
2024-06-12
Accepted
2024-06-12 16:05:31
Documents
14
Period of Report
2024-06-11
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d844802d8k.htm   iXBRL 8-K 37989
2 EX-3.1 d844802dex31.htm EX-3.1 7273
  Complete submission text file 0001193125-24-159933.txt   182934

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA krro-20240611.xsd EX-101.SCH 2892
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE krro-20240611_lab.xml EX-101.LAB 20245
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE krro-20240611_pre.xml EX-101.PRE 12630
18 EXTRACTED XBRL INSTANCE DOCUMENT d844802d8k_htm.xml XML 4231
Mailing Address ONE KENDALL SQUARE. BUILDING 600-700 SUITE 6-401 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE. BUILDING 600-700 SUITE 6-401 CAMBRIDGE MA 02139 617-468-1999
Korro Bio, Inc. (Filer) CIK: 0001703647 (see all company filings)

EIN.: 472324450 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39062 | Film No.: 241038410
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)